Shares of Organon & Co (OGN), a global healthcare company focused on women's health and biosimilars, soared 8.98% in the pre-market session on Thursday, February 13, 2025. The rally was driven by the company's better-than-expected fourth-quarter earnings and an upbeat outlook for 2025.

The key highlights from Organon's Q4 2024 earnings release are:

• Q4 2024 adjusted earnings of $0.90 per share, beating analysts' estimates of $0.87
• Q4 2024 revenue of $1.59 billion, in line with analysts' expectations
• Full-year 2024 revenue of $6.4 billion, up 3% year-over-year on a constant currency basis
• Adjusted EBITDA margin of 30.6% for full-year 2024, driven by strong performance across product lines
• Issued full-year 2025 revenue guidance range of $6.13 billion to $6.33 billion, with an expected adjusted EBITDA margin of 31.0% to 32.0%

The company's robust performance was underpinned by strong sales growth in its key franchises, including Women's Health, led by the contraceptive implant Nexplanon, and Biosimilars, driven by the recently launched Hadlima. Additionally, Organon's acquisition of Dermavant Sciences Ltd. in October 2024 contributed to the diversification of its product portfolio and revenue streams.

Analysts praised Organon's ability to navigate the challenges posed by the loss of exclusivity for its second-largest product, Atozet, in certain markets. The company's proactive cost management strategies and focus on operational efficiency enabled it to maintain robust profitability levels.

Looking ahead, Organon's optimistic 2025 guidance, coupled with its commitment to disciplined capital allocation and strategic acquisitions, instilled confidence in investors regarding the company's long-term growth prospects.